UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Comparative performance of different methods for circulating tumor cell enrichment in metastatic breast cancer patients

PloS one, 2020-08, Vol.15 (8), p.e0237308-e0237308

2020

Link zum Volltext

Verfügbarkeit prüfen

Evaluating Survivorship Care Plans: Results of a Randomized, Clinical Trial of Patients With Breast Cancer

Journal of clinical oncology, 2011-12, Vol.29 (36), p.4755-4762

2011

Link zum Volltext

Verfügbarkeit prüfen

An end too soon?

Canadian Medical Association journal (CMAJ), 2022-02, Vol.194 (7), p.E262

Rayson, Daniel

2022

Link zum Volltext

Verfügbarkeit prüfen

Cardio-Oncology

Journal of clinical oncology, 2021-09, Vol.39 (26), p.2962-2963

Rayson, Daniel

2021

Link zum Volltext

Verfügbarkeit prüfen

Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center

Breast (Edinburgh), 2024-06, Vol.75, p.103715-103715, Article 103715

2024

Link zum Volltext

Verfügbarkeit prüfen

Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy

Canadian journal of cardiology, 2016-07, Vol.32 (7), p.831-841

2016

Link zum Volltext

Verfügbarkeit prüfen

Camouflage

Journal of clinical oncology, 2020-01, Vol.38 (3), p.281-282

Rayson, Daniel

2020

Link zum Volltext

Verfügbarkeit prüfen

Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective

Current oncology (Toronto), 2023-08, Vol.30 (9), p.8019-8038

2023

Link zum Volltext

Verfügbarkeit prüfen

Sweet Surrender

Journal of clinical oncology, 2018-12, Vol.36 (35), p.JCO1801212-3521

Rayson, Daniel

2018

Link zum Volltext

Verfügbarkeit prüfen

Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines

Therapeutic Advances in Medical Oncology, 2022-01, Vol.14, p.17588359211066677-17588359211066677

2022

Link zum Volltext

Verfügbarkeit prüfen

To The Last Drop

Journal of clinical oncology, 2017-09, Vol.35 (26), p.3083-3084

Rayson, Daniel

2017

Link zum Volltext

Verfügbarkeit prüfen

Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain

Current oncology (Toronto), 2022-12, Vol.29 (12), p.9891-9895

2022

Link zum Volltext

Verfügbarkeit prüfen

Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on "Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29 , 9891-9895"

Current oncology (Toronto), 2023-05, Vol.30 (5), p.5050-5053

2023

Link zum Volltext

Verfügbarkeit prüfen

Impact of the COVID-19 Pandemic on Medical Oncology Workload: A Provincial Review

Current oncology (Toronto), 2023-03, Vol.30 (3), p.3149-3159

2023

Link zum Volltext

Verfügbarkeit prüfen

White Knuckling

Journal of clinical oncology, 2016-04, Vol.34 (12), p.1419-1420

Rayson, Daniel

2016

Link zum Volltext

Verfügbarkeit prüfen

On Heartbreak in Oncology

Current oncology reports, 2019-01, Vol.21 (1), p.7-4, Article 7

Rayson, Daniel

2019

Link zum Volltext

Verfügbarkeit prüfen

On denying denial

Journal of clinical oncology, 2013-12, Vol.31 (34), p.4371-4372

Rayson, Daniel

2013

Link zum Volltext

Verfügbarkeit prüfen

Terry Fox: Canadian Cancer Research Activist Whose “Marathon of Hope” Inspired Millions

Mayo Clinic proceedings, 2014-08, Vol.89 (8), p.e75-e76

2014

Link zum Volltext

Verfügbarkeit prüfen

Phase II Multicenter Trial of Anthracycline Rechallenge With Pegylated Liposomal Doxorubicin Plus Cyclophosphamide for First-Line Therapy of Metastatic Breast Cancer Previously Treated With Adjuvant Anthracyclines

Journal of clinical oncology, 2009-12, Vol.27 (35), p.5906-5910

2009

Link zum Volltext

Verfügbarkeit prüfen

The Cost-Utility of Sequential Adjuvant Trastuzumab in Women with Her2/Neu-Positive Breast Cancer: An Analysis Based On Updated Results from the HERA Trial

Value in health, 2009-07, Vol.12 (5), p.641-648

2009

Link zum Volltext

Verfügbarkeit prüfen

Investigations for patients with early-stage breast cancer: oversetting the stage

Canadian Medical Association journal (CMAJ), 2015-09, Vol.187 (12), p.860

2015

Link zum Volltext

Verfügbarkeit prüfen

Parallel lives diverge

Journal of clinical oncology, 2012-06, Vol.30 (16), p.2016-2018

Rayson, Daniel

2012

Link zum Volltext

Verfügbarkeit prüfen

The effects of immunotherapy and novel therapies on medical oncology work load in a Canadian province

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.6532-6532

2019

Link zum Volltext

Verfügbarkeit prüfen

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

The New England journal of medicine, 2021-04, Vol.384 (16), p.1529-1541

2021

Link zum Volltext

Verfügbarkeit prüfen

Negotiations and love songs

Journal of clinical oncology, 2011-02, Vol.29 (6), p.777-778

Rayson, Daniel

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 163

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(159)
Mit Volltextzugriff
(154)

Publikationsform

Sprache

Englisch
(163)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Comparative performance of different methods for circulating tumor cell enrichment in metastatic breast cancer patients

Evaluating Survivorship Care Plans: Results of a Randomized, Clinical Trial of Patients With Breast Cancer

An end too soon?

Cardio-Oncology

Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center

Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy

Camouflage

Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective

Sweet Surrender

Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines

To The Last Drop

Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain

Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on "Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29 , 9891-9895"

Impact of the COVID-19 Pandemic on Medical Oncology Workload: A Provincial Review

White Knuckling

On Heartbreak in Oncology

On denying denial

Terry Fox: Canadian Cancer Research Activist Whose “Marathon of Hope” Inspired Millions

Phase II Multicenter Trial of Anthracycline Rechallenge With Pegylated Liposomal Doxorubicin Plus Cyclophosphamide for First-Line Therapy of Metastatic Breast Cancer Previously Treated With Adjuvant Anthracyclines

The Cost-Utility of Sequential Adjuvant Trastuzumab in Women with Her2/Neu-Positive Breast Cancer: An Analysis Based On Updated Results from the HERA Trial

Investigations for patients with early-stage breast cancer: oversetting the stage

Parallel lives diverge

The effects of immunotherapy and novel therapies on medical oncology work load in a Canadian province

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Negotiations and love songs

Suchergebnisse filtern